Targeted drug trial hopes to shrink tumors in patients with specific gene mutations

NCT ID NCT06630416

Recruiting now Disease control Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

First seen Feb 25, 2026 · Last updated May 18, 2026 · Updated 6 times

Summary

This study tests the drug pemetrexed in people with metastatic bladder cancer or other solid tumors that have certain gene mutations (MLL4, UTX, or MTAP). The drug works by blocking a nutrient cancer cells need to grow. Researchers want to see if it can shrink tumors in these patients. About 64 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IV BLADDER CANCER AJCC V8 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Northwestern Medicine Orland Park
RECRUITING

Orland Park, Illinois, 60462, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Northwestern University
RECRUITING

Chicago, Illinois, 60611, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

METASTATIC BLADDER UROTHELIAL CARCINOMA METASTATIC MALIGNANT SOLID NEOPLASM STAGE IV BLADDER CANCER AJCC V8